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Models for assessing health and economic outcomes of
new drugs have an increasing role in the early phases of
drug development. Their input into go/no go and prior-
ity setting decisions can reveal that further development
of a drug is unattractive from an economic viewpoint, or
that developing a certain indication is more attractive
than another. They may also influence the later choice
of indication, positioning, comparators, length of fol-
low-up, and other elements in the further development
of drugs. Their specific nature, characterized by limited
budget, timelines and data availability should not neces-
sarily lead to compromises in design and conduct. It is
argued that high quality early models form the breeding
ground for later solid evidence on value for money, and
are consequently both worthwhile to the pharmaceutical
industry and to health care decision-makers and payers.
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General Applications of Health Economic 
Evaluations and Modelling
 
The use of health economic evaluations is increasing
and together with this increase, the need for valid,
reliable and transparent results and conclusions has
become more and more explicit. Health economic
evaluations of pharmaceutical drugs, also called
pharmacoeconomic evaluations, are conducted in
different development phases of drugs [1].
In the late stages of development (at the time of
approval for marketing), economic evaluations are
used by the industry to demonstrate a drug’s value
for money towards pharmaceutical pricing and re-
imbursement decision-makers (the payers). The pur-
pose thereby is to show that a given drug is worth
its money [1,2]. For the payers themselves, this in-
formation resulting from economic evaluations of
health care technologies can help them in allocating
their scarce resources efficiently [1,2]. Australia and
Canada were among the first countries applying
these evaluations in their decision-making process,
and were followed by several others.
Once a pharmaceutical drug is on the market,
decisions about formularies (limited lists of al-
lowed drugs) in hospitals [3], and decisions with
regard to optimal medical treatment guidelines
[1,4] may be supported by economic evaluations
as well. Recently, in some countries even decisions
about revision of price and reimbursement deci-
sions for drugs that have been established in the
market for several years have become of interest.
The recent NICE initiative [5,6] in the UK is a typ-
ical example of increased attention and need for
the combined health and economic evidence of
health care interventions, both in the adoption of
new technologies and in the continuous assess-
ment of their value.
Health economic modelling is an often used
technique in health economic evaluations (Khan
and Miller, 99) [7]. Most methodological guide-
lines on the conduct and reporting of health eco-
nomic evaluations advocate the use of modelling
techniques [8], but provide few specific recom-
mendations on which models to use for various
types of analyses. In studies for reimbursement
purposes, models may help to bridge from efficacy
to effectiveness, from short-term results to long-
term results, and offer the decision-maker differ-
ent scenarios with different outcomes, each with
anticipated likelihood. Modelling may also allow
the manufacturer and the decision-maker to pre-
dict, in function of the market potential, the total
budgetary implications of the new drug, if it were
to be adopted. In fact, one important advantage of
models here is that they can overcome the classical
decision-maker’s dilemma, which involves having
to take a decision with regard to adopting a new
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drug (i.e., reimbursing, including on a positive list,
etc.) based on information from randomized clini-
cal trials, without disposing of data on the effec-
tiveness and patterns of usage of the drug in real
life conditions.
 
Purposes of Early Health
Economic Evaluations
 
An apparently less common application of phar-
macoeconomic evaluations takes place in the early
development of innovative drugs (preclinical up to
Phase II). The research and development costs of
new drugs are known to be very high. Grabowski
(97) [9], cites a figure of $US 300 million, and
Miller (98) [10] refers to $US 500 million, al-
though the latter was criticized by Love (99) [11],
since some of these costs, especially preclinical
ones, are not paid by industry. In any event, ac-
cording to Grabowski (97) [9], the majority of
those development costs paid by the companies
themselves come from late development, and sev-
eral important strategic decisions have to be made
during the early development phases, in prepara-
tion for Phase III.
Early models can be used for many purposes
here. The first application is the input into go/no
go and priority setting decisions by the manufac-
turer, as the results can reveal that further devel-
opment of the drug is not interesting from an eco-
nomic viewpoint, or that developing a certain drug
is more attractive than another: preliminary eco-
nomic evaluations of the different drugs in a com-
pany’s pipeline aim at predicting the future eco-
nomic value of those drugs, and are used as one
important criterion in priority setting, in combina-
tion with internal financial and external environ-
mental analyses [12]. A related application is to
guide the decision to focus the further development
in specific indications/patient groups, or in a specific
positioning, in which better value for money can be
expected. Also, it can be decided, based on such an
early economic evaluation, that the further develop-
ment should be in the first place in comparison with
a specific competitor, or that the clinical trials
should have a given time horizon (duration of fol-
low-up), or that the clinical trials should collect
very detailed data on a given parameter (e.g., the
management of a given adverse event, the level of
compliance), since this parameter seems to be a
very sensitive one in the model. Early models can
also be used to identify the optimal sample size for
demonstrating economic differences and key cost
drivers that should be collected prospectively in
phase III studies. These key decisions can influence
future price and reimbursement status of drugs
and hence play a major role in a company’s sales
and profits. To support such decisions, early as-
sessment and estimation of health and economic
outcomes become more and more crucial, and rely
for a large part on modelling techniques [9].
Yet, such early models are rarely reported in liter-
ature, because of their specific purpose to support in-
ternal decisions. Indeed, although in principle eco-
nomic researchers should consider very carefully any
contract that forbids publication [2], when the work
has been carried out rather on a consultancy basis
for the sponsor’s information only, secrecy is re-
quired. Moreover, the external value at the moment
of their conduct is low.
However, it should be realized that the meth-
ods applied and the level of quality of these early
models may be a determining factor in the quality
of the methods applied later on in the develop-
ment of drugs. The specific nature of the design,
conduct and implementation of these early models
and their contrast to models used for reimburse-
ment/listing purposes is therefore of increasing in-
terest.
 
The Specific Nature of Early Models in 
Comparison to Late
 
It can be questioned whether early models should
be differentiated from late phase models at all,
since both rely on the same techniques and meth-
ods. Yet, in contrast to late phase models, in early
models, mostly very scarce data are available with
regard to the new drug, and there is in general an
increased uncertainty around the input variables.
Hence, a so-called anticipated clinical profile of
the new drug is proposed based on either the de-
sires of management in case of targeted research
and/or on deduction from pharmacodynamic proper-
ties of the chemical entity. Even more important, the
objectives and the applications of early models are
also different, namely to inform management about
the potential economic value of the drug in different
conditions and scenarios and to guide the further
development of the drug, as was discussed in the
introduction.
Because of the different objectives and applica-
tion, early models have a specific nature, which is
even more accentuated by the limited budget and
limited timelines. This has some implications with
regard to the design, the methodological conduct
and the implementation of these models, which
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will be discussed below and illustrated with exam-
ples of some published and unpublished models.
 
Design of Early Models
 
Currently, in several countries, health economic
studies are mandated by authorities [13] and the
quality requirements of submitted evaluations are
becoming more explicit. One could argue that
quality is less of an issue in early models. To illus-
trate this, some call these research projects quick-
and-dirty models, whereby the focus is on quick,
and the dirty is considered as an inevitable conse-
quence of the quick. One could argue, however,
that the dirty is rather a consequence of the lack of
data and not of the required rapidity of the work.
The following illustrates that with regard to re-
search design, early models are expected to meet
the requirements of full-blown models.
 
Perspective and Target Audience.
 
A key design
element is the selection of target audience and per-
spective. Although the direct target audience is the
internal management of a company, the model
should be developed as if the external decision-
maker is the target audience, and should therefore
take his/her perspective. Indeed, it is important
from the early stages to understand the previously
mentioned decision-maker’s dilemma and to work
within the decision-maker’s framework. This has
direct relation to the country(ies) of choice for
conducting the model. Ideally, the countries in
which the drug will be marketed, and which are
likely to use economic studies in their decision-
making should be selected. However, there is un-
certainty about which will be these countries when
the drug is approved several years later, and some
of these countries (Canada, Australia) may repre-
sent a relatively small share of the target market. It
is often a good compromise to select two or three
large countries, preferably with a different level of
relative health care expenses, and different health
care payment systems. Besides the US, the UK,
France and Germany, seem to be the most relevant
countries. In published models at a later stage, as
was shown by a Medline search, these countries
are frequently cited as well, with 2218 citations
for the US, 194 for the UK, 191 for Germany, and
120 for France. However, note that in these pub-
lished late models, the countries of research are
not only the above, but also those where pharma-
coeconomic evaluations are required or desired,
such as The Netherlands, Australia and Canada.
The selection of US, France, UK and Germany is
obvious because first, these countries represent
large markets, and second, they show an increas-
ing role for health economic evaluations in pricing
and adoption of new drugs.
Note that in a decision-maker’s perspective,
health economic evaluations have the ultimate goal
of assisting decision-makers in optimizing what-
ever the decision-maker wants to maximize [1]. As
a result, mostly only direct medical costs will be
included in early models, since if it is not possible
to demonstrate benefits on this level it is very un-
likely that the decision-maker will be interested in
direct nonmedical costs or productivity related
costs.
 
Comparators.
 
Another design element is the choice
of comparative treatments in the analysis. One of
the components of methodological guidelines on
which there is large agreement is that the compara-
tor should be the therapy most likely to be replaced
by the one under study [8]. But it is obviously not
always known a priori which therapy will be re-
placed. This is even a larger problem in early as-
sessment models. Hence, the comparative strate-
gies should be those that are expected to be the
main comparators once the new drug arrives on
the market. Because of this selection problem, in
most early models more than one and often three
to four comparators are considered. This may in-
clude currently established therapy, of which fre-
quently the no therapy option may be the most
relevant. It also should include new therapies that
are likely to become established options in the fu-
ture. Moreover, future practice will not necessar-
ily involve new competitor drugs, but also new
medical practice in general (improved diagnostic
techniques, changed hospital management, etc.).
For instance, in an early assessment model of cy-
tomegalovirus infections [14], the question of po-
sitioning a new drug in either pre-emptive (test for
signs of infection and treat pre-emptively to pre-
vent disease) or prophylaxis (preventive treatment
for all regardless of testing) was raised. In the
model, sensitivity and specificity of testing for in-
fection was included in a Bayesian approach in or-
der to assess how future improvement of testing
could affect results.
Finally, the investigated drug could be assessed
at different doses. For example, phase II studies
for a new antithrombotic drug with a very highly
anticipated manufacturing cost, had shown a strong
dose-effect relationship. Early economic analysis
was used as a support in the selection of the dose
to be tested in phase III studies.
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Analytical Technique
 
With regard to the analytical technique, early as-
sessment models analyze the cost-effectiveness of
the drug in development, and should not be re-
stricted to cost analysis. This is because there is
too much uncertainty about the possible differ-
ences in effectiveness between the study drug and
its comparators. So, at least the different efficacy
and effectiveness scenarios should be considered.
The choice of outcomes must anticipate on the
later required outcomes. Often, the literature is
full of surrogate outcomes for a given disease and
no relevant health economic outcomes are avail-
able. Currently, there is an interesting evolution
ongoing in the indirect generation of utility data
from generic health-related quality of life instru-
ments such as SF-36 and EuroQol, facilitating the
production of QALY estimates alongside clinical
trials or in cross-sectional surveys [15]. Early
models can help to assess the importance of utility
changes and can demonstrate the need for assess-
ing utility values for specific medical conditions.
 
Horizon.
 
The time horizon should as usual per-
mit inclusion of all relevant costs and effects. But,
again, not all relevant costs and effects are neces-
sarily known, and if they are known, it is not al-
ways clear how far in the future they will occur,
and to that extent they will have an impact on
health care decisions. Hence, in early models, the
time horizon may also be used as an uncertain
variable and its effects may be tested in sensitivity
analyses. For instance in a recently conducted
early assessment model in ulcerative colitis, a time
horizon of at least one year and a reduction of sys-
temic complications of ulcerative colitis by at least
50% was necessary to obtain cost-effectiveness for
a new disease modifying drug. This suggested that
later prospective economic evaluations should be
designed as long-term studies and that the clinical
program should also address the issue of systemic
complications and not just the gastrointestinal
condition of the patient.
 
Data Sources.
 
Finally, the sources of data for re-
source use and effects are quite different from
later studies. Clinical data regarding established
comparators will be obtained from literature, while
the data of the study drug and anticipated future
competitors are mostly based on an anticipated
profile resulting from preclinical and early (up to
phase II) clinical evidence or expert opinion. Re-
source use data may be derived from literature,
databases or expert opinion. It should thereby be
remembered that measurement of costs and ef-
fects is not a costless activity [2]. Hence, a key con-
sideration in early trials is to weigh the accuracy
and credibility of the data against the cost of ob-
taining it. This is further discussed in the next
paragraph.
Table 1 provides an overview of early assessment
models conducted at HEDM. The table illustrates
the large number of comparators, the flexible time
horizon, and the reliance on desk research/expert
opinion for data collection.
 
Key Steps in The Development of Early Models
 
The steps described for the development of early
models cover the entire process from start to end,
although it should be recognized that many early
models have no real ending since their structure is
supposed to survive throughout the product’s life-
time. The development of early models is quite
different from late stage models, since the deadline
for delivering results is shorter, and the budgets
are limited. There is also an apparent contradic-
 
Table 1
 
Overview of major design aspects of some early economic assessments conducted at HEDM
 
Disease area
Type of
model Countries Perspective
#
comparators
Time 
horizon
Clinical data 
competitors Cost data
Diabetes type 2 Decision tree UK, FR, GER payer 5 fixed Clinical trials Database
Lyme disease Decision tree US payer 2 flexible Clinical trials Literature, Delphi panel
Prevention of DVT Decision tree UK hospital 4 flexible Clinical trials Literature
NSAID related 
gastrotoxicity Decision tree UK, US payer 5 flexible Clinical trials Literature
Antifungal therapy in 
febrile neutropenia Decision tree UK hospital 3 fixed Clinical trials Delphi panel
Ulcerative colitis Markov FR payer 3 flexible Clinical trials Literature
Crohn’s disease Spreadsheet US payer 4 flexible Clinical trials Literature
BPH Markov UK, NL payer 5 flexible Clinical trials Delphi panel
Cytomegalovirus Decision tree UK, FR, GER payer 6 Flexible Clinical trials Delphi panel
Non-small cell lung 
cancer Spreadsheet EUR payer 2 fixed Clinical trials Literature
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tion between the limited data availability and the
large variety of options to be assessed. What is the
solution? The key aspect is not to make compro-
mises with regard to the correct collection of clini-
cal data nor to the structure of the model.
 
Clinical Data Collection.
 
With regard to the clini-
cal data, wrongly assessed data will lead in general
to large errors in cost estimates, savings and cost-
effectiveness. For instance, in an early assessment
model of the management of Benign Prostate Hy-
pertrophy (BPH), the choice of clinical data on ex-
isting drugs with regard to the possible prevention
of prostate surgery had a major impact on the final
outcomes. A very careful analysis, among others—
inclusion/exclusion criteria, efficacy assessment and
reasons for and circumstances of drop-outs—is
therefore required to revise and reapply the results
of trials. Sometimes, especially given the large
number of comparators, assumptions need to be
made in terms of relative differences between com-
parators. A so-called pivotal drug is then selected
based on its presence in different trials comparing it
with different alternatives. Table 2 illustrates this
problem. If for instance drug A is compared with
drug B in trial 1, and drug B with drug C in trial 2,
then drug B is called the pivotal drug. Suppose effi-
cacy results (here percentage of responders) are as
shown in the table. The estimates used in the model
can be derived by taking the absolute values of trial 1,
and by simple extrapolation of the relative effect of C
vs. B. But one might as well take the absolute values
of trial 2 and the relative effect of A vs. B. One
could also challenge the relative extrapolation and
apply an absolute extrapolation, which will again
lead to different figures in the model. The different
scenarios must be tested for their effect on the fi-
nal results, and discussed with clinical experts.
 
Model Building.
 
In case of absence of sufficient
comprehensiveness of the model, the required out-
come cannot be delivered. For instance, if it is not
clear whether a new oral drug for the treatment of
diabetes should replace the existing oral drugs or
rather be positioned in between current oral treat-
ment and insulin treatment, all these options must
be modeled [16]. If a new NSAID is to be assessed
 
with regard to the economic consequences of re-
duced gastrotoxicity, the model should take into
account the different subpopulations that are at
different risk for gastrotoxicity, to assist in the po-
sitioning of the drug [17].
It is often a misconception that the level of
comprehensiveness is linearly related with the ef-
forts and budget involved. A comprehensive model
rather requires creative thinking and programming
and adapted software tools. Bloom and Bloom
(99) [18] describe a complex system as one in
which the relationships between inputs and out-
puts are nonlinear and in which the interactions
are complicated and convoluted. Such systems are
usually characterized by an enormous number of
inputs and an even larger number of interactions,
making it difficult to predict accurately all impor-
tant outcomes, but providing the framework for
multiple scenario analysis, which is exactly the
need in early modelling.
 
Resource Use and Cost Data Collection.
 
Often,
if compromises need to be made, these are best
made on the quality and/or validity of the cost esti-
mates [19]. Mostly, costs will be the result of re-
source use data collected from a small number of
experts, multiplied with unit costs per resource (of-
ten charges if the public payer’s perspective is cho-
sen). Expert judgement is justified by the low bud-
get involved, and by some evidence from literature
that, if well designed, these methods are reliable
[20–23]. Sometimes, literature cost data are avail-
able and applied, although these data may come
from countries which are not of interest at that
point, or from a long past costing year. Recalcula-
tion using actualization techniques to overcome the
time issue, and proportional comparison of the
health care expense levels of the source country
and the target country(ies) may help to resolve the
issue. For instance, in an early analysis of a new
chemotherapy in patients with metastatic colorec-
tal cancer, the anticipated profile of the drug in-
volved a strong reduction in hematological and
nonhematological adverse events. The costs of
managing those adverse events were obtained from
five different countries for which an average value
in Euros (
 
€
 
) was calculated [24].
 
Table 2
 
Example of the application of a pivotal drug in an early assessment model
 
Trial 1 Trial 2 Model (rationale 1) Model (rationale 2) Model (rationale 3) Model (rationale 4)
Drug A 60% 60.0% 53.1% 60% 52%
Drug B 70% 62% 70.0% 62.0% 70% 62%
Drug C 78% 88.1% 78.0% 86% 78%
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This approach is allowed if different sensitivity
analyses varying the costs over large ranges (
 

 
30%)
assist in assessing the possible impact of errors in
estimating costs. In our experience, the influence of
costs in such models is consistently smaller than the
influence of clinical data.
 
Results and Sensitivity Analysis.
 
According to Mul-
lins and Ogilvie (98) [8], the greatest contribution
resulting from pharmacoeconomic models is often
their ability to document a range of plausible out-
comes and ratios during sensitivity analysis. Sen-
sitivity analysis, or, more generally stated, un-
certainty analysis, is implicit to early assessment
models and is perhaps the most important aspect
in the conduct of early models. It should be em-
phasized that two goals of uncertainty analysis are
envisaged here: first, to test the robustness of the
outcomes, and second, to perform scenario analy-
ses to assess the impact of selected interventions
on outcomes. For instance, drug clinical features
(e.g., improved efficacy, reduced or in some cases
increased adverse event rates, improved utility,
improved compliance, etc.) and economic features
(e.g., anticipated acquisition cost features, changes in
management, etc.). Different types of sensitivity anal-
yses can be applied [25,26]: simple sensitivity analysis
(one-way, two-way, three-way), threshold analysis,
and analysis of extremes and probabilistic sensitivity
analysis. (Einarson et al. 95) [27] have proposed the
ROSA (rank order stability analysis) technique, by
which all variables in a model are varied and for
each the level at which the rank order of alterna-
tives changes is identified. Also, first order or sec-
ond order Monte Carlo analysis (Doubilet et al.
85) [28] of models can assist in determining sam-
ple size of subsequent clinical/economic trials. For
instance, in an analysis assessing the present value
cost of metastatic colorectal cancer, a Monte Carlo
evaluation of the model resulted in estimates of the
average cost and the standard deviation of medical
management [17] and was applied in the establish-
ment of the sample size for a later phase III trial.
 
Implementation of Early Models
 
An important element in the implementation of
early models is the way the development of the
early model is structurally organized within a
company. Ideally, the decision to undertake early
assessment models should be taken by a drug de-
velopment group, a committee consisting of mem-
bers from the clinical, marketing, regulatory and
health economic departments. Members of such a
group should be aware from start, of the possible
impact of the results on the development strate-
gies, go/no go decisions, and consequences for
phase III and later. As more data become avail-
able, the model can be updated and recalculated.
A key list of variables can be created and linked to
the model’s calculating engine. By adjusting those
variables, new results can be produced and calcu-
lations from the past can be revised. As such, the
same model can also be adapted to other country
settings in order to calculate country-specific cost-
effectiveness ratios. Ideally, the predictions of early
models are confirmed by phase III outcomes. This
was recently illustrated with a model in fungal dis-
ease, which predicted the outcome of the phase III
clinical results in terms of efficacy, adverse events
and health economics [30,31].
 
The Future of Early Models
 
According to Thwaites and Townsend (98), the
demand from decision-makers for pharmacoeco-
nomic data is expected to expand in the future
[29]. Together with this growing demand, users of
pharmacoeconomic evaluations will become more
knowledgeable in interpreting and using the data,
and they will raise the rigor of data that will be
considered acceptable. At the same time, a grow-
ing need for collaborative studies between indus-
try and its customers is expected, whereby study
design, data gathering and data interpretation will
become joint tasks. This evolution will automati-
cally have early implications in the drug pipelines
of pharmaceutical companies.
The key purpose for early assessment models is
to incorporate the economic dimension in strate-
gic development decisions for a new drug, by pro-
viding multiple, rigorous but understandable anal-
yses on the health and economic impacts of this
new drug under different scenarios. As a conse-
quence, early assessment models should not com-
promise on the quality of design, but given the
smaller budgets and shorter deadlines, may com-
promise somewhat on the intensity and efforts in
data collection. On the other hand, more efforts
should be assigned to uncertainty analysis, explor-
ing more variables (such as time horizon, posol-
ogy, cross-country cost differences, changes in
medical practice, etc.). Also, more comparators
should be involved, and finally, different position-
ing and different target patient groups should be
analyzed.
A crucial feature of early models is indeed that,
if they are well designed and take into account the
key elements of medical management and out-
 Early Health Economic Models
 
433
 
comes for a given disease, they can be useful
throughout the entire lifetime of a drug, and facili-
tate further evaluations. In the case of limited quality
of design they may negatively influence the design
quality in later stage analyses, hence provoking justi-
fied questions from decision-makers, and allowing
competitors later on to place their own interpreta-
tion on study results [2]. Therefore, it is in everyone’s
interest (industry and decision-makers) that these
quick-and-dirty models have the same or even more
careful design considerations as late stage models.
As a result, early models may become, as pre-
dicted several years ago [12], a cornerstone in deci-
sion-making in the further development of drugs.
 
This study was partially funded by Aventis, Paris, France.
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